CRISPR Therapeutics (CRSP): ARK's Stock Stories
For 30 years, the standard of care for sickle cell disease was a drug that managed symptoms without touching the underlying genetic defect. In December 2023, the Food And Drug Administration (FDA) approved a functional cure. CASGEVY, built by CRISPR Therapeutics and commercialized with Vertex Pharmaceuticals, has treated less than 0.1% of its 60,000 eligible patients. ARK’s bottoms-up model sees roughly $5 billion in cumulative revenue through 2029, versus Wall Street consensus of $1 to 2 billion.
Your brain may not actually “make” decisions
A neuroscientist is challenging the idea that the brain contains a central system that actually “makes” our decisions. What we experience as choosing may instead emerge from the continuous interaction of perception, movement, the body, and the world ar…
Forces deep inside Earth helped Antarctica freeze before the Arctic
Scientists may have solved the mystery of why Antarctica froze millions of years before the Arctic. Slow-moving waves deep inside Earth gradually lifted East Antarctica, building mountains and a high plateau where snow and ice could survive even in a m…